Quantification of BCR::ABL1 transcript levels in peripheral blood is the gold standard for managing CML patients undergoing tyrosine kinase inhibitor (TKI) therapy. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.